• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » JLL Partners to acquire BioClinica and CoreLab Partners

JLL Partners to acquire BioClinica and CoreLab Partners

January 30, 2013
CenterWatch Staff

BioClinica, a global provider of clinical trial management solutions, has entered into a definitive agreement to be acquired by a holding company controlled by JLL Partners, a private equity firm.

Simultaneously, JLL Partners has reached a definitive agreement to acquire CoreLab Partners, a provider of medical imaging solutions and cardiac safety services based in Princeton, N.J.

Following the proposed acquisitions, BioClinica and CoreLab Partners will be merged to create a provider of medical imaging services and eClinical solutions for clinical trials. Ampersand Capital Partners, the majority owner of CoreLab Partners, also will be a significant investor in the combined company.

Mark L. Weinstein, currently president and CEO of BioClinica, will lead the combined company.

"We are excited about the tremendous promise of this business combination given the strong fundamentals of each company and the overall industry,” said Dan Agroskin, managing director of JLL Partners. “We will conservatively capitalize the combined business and look forward to supporting its continued growth."

Under the BioClinica agreement, the holding company will commence a cash tender offer to purchase all of BioClinica's common stock at $7.25 a share, an equity value of approximately $123 million. Any BioClinica shares not tendered in the offer will be acquired in a second-step merger at the same cash price. The purchase price represents a premium of 23.2% over its average closing price for the 90 days ended Jan. 29, 2013, and 28.7% over the average price for the 52-week period ended Jan. 29, 2013. BioClinica's board has unanimously approved the definitive merger agreement.

David E. Nowicki, DMD, chairman of the board of BioClinica and chairman of its strategic committee said, "After careful and thorough analysis, together with our independent advisors, the strategic committee of our board has endorsed this transaction as being in the best interest of the company and our shareholders."

Following the acquisition, BioClinica will become a privately held company and its stock will no longer trade on the NASDAQ stock exchange. The proposed acquisition of CoreLab Partners is contingent on the closing of the BioClinica transaction. Both acquisitions are expected to close concurrently.

BioClinica provides integrated, technology-enhanced clinical trial management services. It offers imaging core labs on two continents, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management and clinical supply chain forecasting and optimization solutions. With more than 20 years of experience and over 2,000 trials, BioClinica has supported the clinical development of many new medicines from early phase through final approval. It has offices in the U.S., Europe and Asia.

CoreLab Partners offers medical image management, interpretation and response assessment for clinical trials with a particular focus on oncology, regulatory support and digital image submission, cardiac safety assessments for development programs, support for clinical studies and equipment rental, worldwide ambulatory blood pressure monitoring services, digital ECG services and cardiac safety services.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing